Acurx Pharmaceuticals enters $17M ATM equity offering with A.G.P.

Acurx Pharmaceuticals, Inc.

Up to $17M of common stock may be sold from time to time in at-the-market offerings.
A.G.P./Alliance Global Partners acts as sales agent, receiving 3% of gross proceeds.
Sales may be made on Nasdaq Capital Market, OTC, or in negotiated transactions.
Company is not obligated to sell any shares under the agreement.
Offering made under existing Form S-3 shelf registration statement declared effective July 2022.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Acurx Pharmaceuticals, Inc. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at up to $17.0 million (effective 2023-11-15).

Action: entry
Agreement: atm program
Counterparty: A.G.P./Alliance Global Partners
Value: up to $17.0 million
Effective: 2023-11-15

Exact text from the filing

On November 15, 2023, Acurx Pharmaceuticals, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement” and such transactions contemplated thereby, the “ATM Program”) with A.G.P./Alliance Global Partners (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $17.0 million through the Sales Agent, acting as agent.

View on SEC.gov

Browse all material agreements →

Acurx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-118749

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.